공고 • Jul 16

Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States

Bausch + Lomb Corporation announced the U.S. launch of the EyeGility Inserter preloaded IOL delivery system. EyeGility is designed for the enVista family of IOLs. EyeGility inserter offers balanced push force for smooth delivery, convenient one-handed operation. EyeGility Inserter is available now for enVista Aspire; will be available for enVista Envy in the coming months. Designed specifically for preloaded enVista Aspire IOLs and Envy IOLs, the EyeGility inserter offers convenient one-handed operation and balanced push force for smooth delivery, with a silicone soft-tipped plunger that supports reliable IOL delivery with injection through a 2.4mm incision. The inserter provides improved comfort compared to previous Bausch + Lomb inserters, and the loading process allows for up to 20 minutes of standby time from prep to lens delivery. The EyeGility Inserter is now available in the U.S. as part of the enVista Aspire preloaded IOLs. enVista Envy lenses preloaded into EyeGility inserters will be available in the coming months. The EyeGility inserter for enVista preloaded is indicated for folding and inserting of enVista IOL models approved for use with this IOL insertion device as indicated in the IOL approved labeling. Use with other enVista IOL models is likely to cause damage to the IOL and/or inserter and may result in eye damage. Store at room temperature. Do not freeze. Avoid high temperatures (>43° C/109°F). Do not use if the packaging is exposed to environmental conditions outside of those specified. Keep dry. Keep away from sunlight. Folding and compression of the lens should be done just prior to insertion and delivery. Failure to follow the instructions for use may result in patient injury. Prior to opening, inspect the blister tray for signs of damage that may affect integrity of device sterility. If damaged, do not use. If the insertion system fails to properly deliver the lens, use a new IOL and a new inserter. Federal law restricts this device to sale by or on the order of a physician. Reference the Directions for Use labeling for a complete listing of directions for use, indications and important safety information. The enVista Aspire hydrophobic acrylic IOL (non-preloaded model EA) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia following removal of a cataractous lens. The Aspire IOL uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus. However, clinically meaningful extension of the depth of focus has not been demonstrated in clinical trials. Physicians considering IOL implantation under any of the following circumstances should weigh the potential risk/benefit ratio: (1) Recurrent severe anterior or posterior segment inflammation or uveitis; (2) Patients in whom the IOL may affect the ability to observe, diagnose, or treat posterior segment diseases; (3) Surgical difficulties at the time of cataract extraction, which might increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss); (4) A distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is not possible; (5) Circumstances that would result in damage to the endothelium during implantation; (6) Suspected microbial infection; (7) Patients in whom neither the posterior capsule nor zonules are intact enough to provide support. Neither the safety and effectiveness, nor the effects of the Aspire IOL optical design on depth of focus, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have been evaluated clinically. MTF testing of the Aspire IOL optical design (used in model ETA) may aid the surgeon in understanding the theoretical image quality expected with the Aspire IOL compared to the enVista monofocal IOL MX60E. However, these do not fully assess all aspects of clinical difficulties under all conditions. Surgeons must weigh the potential benefits of the modified optical design of the Aspire IOL (model ETA) against the potential for risks associated with a degradation in vision quality and the lack of clinical data to characterize the impact of the Aspire IOL optical design on contrast sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain pre-existing ocular conditions (prior corneal refractive surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc.) or intraoperative conditions (posterior capsular rupture, complications in which the IOL stability could be compromised, inability to place IOL in capsular bag, etc). The safety and effectiveness of the IOL have not been substantiated in patients with pre-existing ocular conditions and intraoperative complications. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting an IOL in a patient with one or more of these conditions. Physicians considering IOL implantation in such patients should explore the use of alternative methods of aphakic correction and consider IOL implantation only if alternatives are deemed unsatisfactory in meeting the needs of the patient. Patients with preoperative problems, such as corneal endothelial disease, abnormal cornea, macular degeneration, retinal degeneration, glaucoma, and chronic drug miosis may not achieve the visual acuity of patients without such problems. The physician must determine the benefits to be derived from IOL implantation when such conditions exist. Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon transient or persistent glaucoma, and secondary surgical intervention. Secondary surgical interventions include but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair. Federal law restricts this device to sale by or on the order of a physician.

공고 • Apr 30

Bausch + Lomb Corporation Features More Than 40 Scientific Studies At The Association For Research In Vision And Ophthalmology Annual Meeting

Bausch + Lomb Corporation announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company’s broad portfolio of products including LUMIFY redness reliever eye drops, Blink NutriTears nutritional supplement, XIIDRA (lifitegrast ophthalmic solution) 5%, MIEBO (perfluorohexyloctane ophthalmic solution), INFUSE/ULTRA ONE DAY daily disposable contact lenses, Biotrue ONEday daily disposable contact lenses, enVista Envy Full Visual Range intraocular lenses (IOLs) and Stellaris Elite Vision Enhancement System. New data will also be presented on pipeline assets including the enVista Beyond extended depth of focus lens and investigational candidates in glaucoma, neuropathic pain, age-related macular degeneration (AMD) and lens care. Paper Presentations: “Effect of Physician Recommendation of AREDS2 Supplements on Structural Biomarkers of AMD Progression.” D. Chen et al. “The Effect of BL1107 on Intraocular Pressure and Visual Function in a Phase 2 Randomized Clinical Trial in Patients With Glaucoma or Ocular Hypertension.” S. Whitcup et al. “Disinfection Efficacy of a New Dual-Disinfectant Investigational Multi-Purpose Solution and Comparator Multi-Purpose Solutions Against Acanthamoeba Trophozoites.” W. Domm et al. Poster Presentations: “Examination of the Effects of Hyaluronic Acid on Cellular Metabolic Activity in Transformed Human Conjunctival and Corneal Epithelial Cells Exposed to Desiccation Stress” K. VanDerMeid et al. “Examination of the Effects of Glycerin on Cellular Metabolic Activity in Transformed Human Conjunctival and Corneal Epithelial Cells Exposed to Desiccation Stress.” J. Russell et al. “Patient-Reported Outcomes of a Supplement in Adults With Dry Eye Disease: A 56-Day In-Home Usage Study.” J. Poteet et al. “Global Unmet Needs in Dry Eye: A Comparative Assessment Across the United States and Five International Populations.” R. Ryan et al. “A Phase 3 Randomized Trial of a Novel Brimonidine Tartrate Ophthalmic Solution With Sodium Hyaluronate.” S. Kannarr et al. “Comparative Analysis of AREDS2 and AREDS2+B Vitamin Complex in an in vitro Model of Age-Related Macular Degeneration.” R. Srinivasagan et al. “Clinical Outcomes and Patient Experience Following IOL Exchange With a Full Visual Range Intraocular Lens.” R. Wong et al. “Outcomes of a Novel Full Visual Range Intraocular Lens in Eyes With Previous Corneal Refractive Surgery.” J. Wong et al. “Visual Outcomes at Different Distances With a Full Visual Range Intraocular Lens, a Case Series Study.” G. Lau et al. “Halo Characterization of Two Extended Range of Vision Intraocular Lenses.” J. Antonio Azor Morón et al. “Optical Evaluation of Halos in Multifocal Intraocular Lenses.” L.Nijm et al. “Optical Quality of Two Refractive Full Range of Vision Intraocular Lenses: Impact of Tilt and Decentration.” F. Vega et al. “Intermediate Vision Outcomes of Monofocal Intraocular Lenses Following Cataract Extraction: A Retrospective Cohort Study.” Schavee P et al. “Impact of IOL Asphericity on Simulated Defocus Curves.” F. Alba-Bueno et al. “Corneal Incision Temperature During Phaco Energy Activation - An ex vivo Comparative Study.” A. Papour et al. “Impact of Flow Rate and Ultrasound Energy on Viscoelastic Erosion in a Model Eye.” G. Higgins et al. “Early Outcomes of Standalone Excimer Laser Trabeculostomy in Open Angle Glaucoma: A Prospective Washout Study.” Patel B et al. “Real-World Characteristics of Autoimmune Patients With Dry Eye Disease Treated With Lifitegrast: Insights From the AAO IRIS Registry.” C. Koetting et al. “Physician Perspectives on the Clinical Use of Concomitant Perfluorohexyloctane and Lifitegrast in Dry Eye Disease Management: Results From a Nationwide Survey.” F. Mah et al. “BL1312 Significantly Reduces Pain Over 24 Hours Following Photorefractive Keratectomy: A Sum of Pain Intensity Differences Analysis.” L. Rajagopalan et al. “Risk Factors for Contralateral Eye Involvement in Non-Arteritic Anterior Ischemic Optic Neuropathy: A Retrospective Cohort Analysis of Electronic Health Records.” E. Donovan et al. “BL1332, a TRPV1 Antagonist, Reduces Capsaicin-Induced Acute Ocular Pain in a Rat Model.” V Vozella et al. “The Effects of BL1332, a novel TRPV1 Antagonist, on Corneal Wound Healing Rate and Corneal Sensitivity.” L. Christie et al. “A Novel Alpha2-Adrenergic Receptor Agonist, BL1106, has Structural and Functional Benefits in a Blue Light Model of Retinal Degeneration.” C. Harrower et al. “Retinal Bioavailability and Functional Effects of a Deuterium Labelled Very-Long-Chain Polyunsaturated Fatty Acid (VLC-PUFA) in Wild-Type and Transgenic Mice.” J. Bound David et al. “Early Response to Treatment With Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease: A Post Hoc Analysis of Two Randomized Trials.” J. Sheppard “Preoperative and Postoperative Treatment With Perfluorohexyloctane Ophthalmic Solution in Patients Undergoing Cataract Surgery: Effects on Signs and Symptoms of Dry Eye Disease.” E. Liang “Effects of Preoperative Treatment With Perfluorohexyloctane Ophthalmic Solution on Refractive Outcomes in Patients With Dry Eye Disease Undergoing Cataract Surgery.” J. Bacharach “Retrospective Real-World Evidence Study of Clinical Outcomes and Eyecare Practitioner Satisfaction With Topical Latanoprostene Bunod in Patients With Ocular Open-Angle Glaucoma or Ocular Hypertension.” N. Cothran et al. “Durability of Suprachoroidal Triamcinolone Acetonide in Eyes With Chronic Cystoid Macular Edema in Real-World Clinical Practice.” A. Talwar et al. “Suprachoroidal Triamcinolone Acetonide for Macular Edema: Real World Safety and Efficacy Outcomes From a Tertiary Eye Center.” A. Mobasserian et al. “Disinfection Efficacy of Acanthamoeba Trophozoites by Rigid Gas Permeable Contact Lens Care Products.” H. Wheeler et al. “Clinical Evaluation of a New Multi-Purpose Solution for Soft Contact Lens Wearers.” G Wesley et al. “Regimen Evaluation of a Biotrue Hydration Plus Multi-Purpose Solution Against ISO Microbial Organisms.” T. Bassage “Real-World Assessment of a Multi-Purpose Contact Lens Solution in Contact Lens Wearers With Heavy Digital Device Use and Contact Lens-Related Dryness.” J. Tsai et al. “A Meta-Analysis of the Safety of Nesofilcon a Soft Daily Disposable Hydrogel Contact Lenses.” K. Hoffman et al. “Real-World Evaluation of Patient Satisfaction and Experience With a Novel Daily Disposable Toric Contact Lens.” K. Bhagat et al. “New Contact Lens Wearers’ Real-World Experience and Satisfaction With a Novel Daily Disposable Toric Contact Lens.” J. Womack et al. XIIDRA Indications and Important Safety Information Indication Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Medical Equipment 이익 성장	16.9%
매출 성장률	5.4%
향후 자기자본이익률	7.31%
애널리스트 커버리지	Good
마지막 업데이트	04 Aug 2026

날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	6,121	305	607	847	10
12/31/2027	5,807	110	453	664	13
12/31/2026	5,493	-61	297	531	13
6/30/2026	5,324	-171	137	458	N/A
3/31/2026	5,208	-219	1	340	N/A
12/31/2025	5,101	-360	-66	283	N/A
9/30/2025	4,976	-305	-196	169	N/A
6/30/2025	4,891	-273	-165	186	N/A
3/31/2025	4,829	-362	-168	166	N/A
12/31/2024	4,791	-317	-59	232	N/A
9/30/2024	4,684	-368	-58	225	N/A
6/30/2024	4,495	-456	-137	119	N/A
3/31/2024	4,314	-337	-131	80	N/A
12/31/2023	4,146	-260	-198	-17	N/A
9/30/2023	3,969	-207	-20	127	N/A
6/30/2023	3,904	-141	-57	106	N/A
3/31/2023	3,810	-104	116	286	N/A
12/31/2022	3,768	6	170	345	N/A
9/30/2022	3,773	58	144	348	N/A
6/30/2022	3,780	136	398	594	N/A
3/31/2022	3,773	175	482	688	N/A
12/31/2021	3,765	182	680	873	N/A
9/30/2021	3,708	-78	636	845	N/A
6/30/2021	3,675	-53	539	776	N/A
3/31/2021	3,517	-44	370	618	N/A
12/31/2020	3,412	-18	263	522	N/A
12/31/2019	3,778	298	N/A	799	N/A
12/31/2018	3,665	710	N/A	763	N/A

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/08/10 05:23
종가	2026/08/10 00:00
수익	2026/06/30
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Travis Steed	BofA Global Research
Joanne Wuensch	Citigroup Inc
Philip Chickering	Deutsche Bank

Bausch + Lomb 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Corporation Revises Earnings Guidance for the Year 2026

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2026

Price target increased by 7.4% to US$16.43

Consensus EPS estimates fall by 12%

Bausch + Lomb Corporation Provides Updated Guidance for the Full Year 2025

Recent updates

Bausch Health CEO Appio to Join Bausch + Lomb Board Following Director Reshuffle

Bausch + Lomb Announces Board of Directors Changes, Effective August 5, 2026

BLCO: Eyecare Sector Strength And New Product Launches Will Support Upside

Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States

Bausch + Lomb Ends Glaucoma Eye Drop Trial Plans Implant Study for Geographic Atrophy

BLCO: Fair View Balances Medtech Strength With Pipeline And Execution Risks

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Bausch + Lomb Introduces Orphia, an Ai-Powered Digital Health Platform

Bausch + Lomb Corporation to Report Q2, 2026 Results on Jul 29, 2026

BLCO: Product Pipeline And Higher 2026 Revenue Outlook Will Support Upside

Bausch + Lomb Stock Gains Exposure to New Corneal Disease Treatment With Emmecell Investment

Bausch + Lomb Launches Blink Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher

Bausch + Lomb Expands Eye Health With AREDS3 Launch and Strong Growth in Dry Eye Portfolio

Bausch + Lomb Corporation Launches PreserVision AREDS3 Eye Vitamins In The United States

Executive VP & CFO exercised options to buy US$988k worth of stock.

Bausch + Lomb Corporation Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb Corporation Revises Earnings Guidance for the Year 2026

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Features More Than 40 Scientific Studies At The Association For Research In Vision And Ophthalmology Annual Meeting

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

$BLCO $BHC $COO file their ARS annual financial reports and Proxy statements stating divestiture of Lens Care Vision units but no announcem

$BLCO $BHC $COO BHC’s ARS clearly states the divestment and discontinuation of the Vision Care Business! When will the finally announce!

$Cooper $Bausch + Lomb Corporation DEAL‑CERTAINTY SCORECARD (Final, Fully Integrated Version from AI and my opinion Score: 100/100 — Maxi

Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update

Bausch + Lomb Corporation Announces New Scientific Data and Educational Events At the American Society of Cataract and Refractive Surgery Annual Meeting

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

Bausch + Lomb Corporation to Report Q1, 2026 Results on Apr 29, 2026

Bausch + Lomb Corporation Announces Positive 24-Month U.S. Data on the Elios System for Treatment of Glaucoma

CEO & Chairman exercised options to buy US$10m worth of stock.

Bausch + Lomb Corporation, Annual General Meeting, May 20, 2026

CEO & Chairman exercised options and sold US$1.2m worth of stock

Bausch + Lomb Corporation Announces That Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY

Full year 2025 earnings: EPS misses analyst expectations

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2026

Bausch + Lomb Corporation to Report Q4, 2025 Results on Feb 18, 2026

Bausch + Lomb Corporation Announces Board Appointments, Effective January 1, 2026

Price target increased by 7.4% to US$16.43

Consensus EPS estimates fall by 12%

Third quarter 2025 earnings: EPS misses analyst expectations

Bausch + Lomb Corporation Provides Updated Guidance for the Full Year 2025

Bausch + Lomb Corporation to Report Q3, 2025 Results on Oct 29, 2025

Bausch + Lomb Announces Publication of enVista Envy™? Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Bausch + Lomb Announces Publication of Data from A Prospective Study Evaluating the Efficacy of XIIDRA®? in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Bausch + Lomb Corporation Launches ASANA Gas Permeable Lenses in the United States

Bausch + Lomb Announces Board Changes

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bausch + Lomb Corporation Updates Earnings Guidance for the Full Year of 2025

Bausch + Lomb Corporation Announces Publication of Phase 3 Data on Lumify®? Preservative Free Redness Reliever Eye Drops

Bausch + Lomb Corporation Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions About Dry Eye

Bausch + Lomb Corporation to Report Q2, 2025 Results on Jul 30, 2025

Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

Bausch + Lomb Launches New LUMIFY Preservative Free Redness Reliever Eye Drops in the United States

Bausch + Lomb Corporation Launches Zenlens Chroma Hoa in the United States

Consensus EPS estimates fall by 298%

Bausch + Lomb Corporation Receives European Ce Mark Approval for Preloaded Luxlife Full Range of Vision Intraocular Lens

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2025

Bausch + Lomb Corporation Announces enVista Intraocular Lenses to Market Following Voluntary Recall

Price target decreased by 8.7% to US$18.86

Bausch + Lomb Corporation to Report Q1, 2025 Results on Apr 30, 2025

Bausch + Lomb Corporation, Annual General Meeting, May 21, 2025

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Full year 2024 earnings: EPS misses analyst expectations

Bausch + Lomb Provides Update on Potential Sale

Bausch + Lomb Corporation to Report Q4, 2024 Results on Feb 19, 2025

Bausch + Lomb Corporation Launches enVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in European Union